571 related articles for article (PubMed ID: 15475948)
21. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma.
El-Bassiouni A; Nosseir M; Zoheiry M; El-Ahwany E; Ghali A; El-Bassiouni N
APMIS; 2006 Jun; 114(6):420-7. PubMed ID: 16856963
[TBL] [Abstract][Full Text] [Related]
22. Mnt-deficient mammary glands exhibit impaired involution and tumors with characteristics of myc overexpression.
Toyo-oka K; Bowen TJ; Hirotsune S; Li Z; Jain S; Ota S; Escoubet-Lozach L; Garcia-Bassets I; Lozach J; Rosenfeld MG; Glass CK; Eisenman R; Ren B; Hurlin P; Wynshaw-Boris A
Cancer Res; 2006 Jun; 66(11):5565-73. PubMed ID: 16740691
[TBL] [Abstract][Full Text] [Related]
23. High-throughput tissue microarray analysis of c-myc activation in chronic liver diseases and hepatocellular carcinoma.
Chan KL; Guan XY; Ng IO
Hum Pathol; 2004 Nov; 35(11):1324-31. PubMed ID: 15668888
[TBL] [Abstract][Full Text] [Related]
24. T-cell lymphomas mask slower developing B-lymphoid and myeloid tumours in transgenic mice with broad haemopoietic expression of MYC.
Smith DP; Bath ML; Harris AW; Cory S
Oncogene; 2005 May; 24(22):3544-53. PubMed ID: 15688022
[TBL] [Abstract][Full Text] [Related]
25. Tumour growth inhibition by an imidazoquinoline is associated with c-Myc down-regulation in urothelial cell carcinoma.
Liu H; Schwartz MJ; Hwang DH; Scherr DS
BJU Int; 2008 Apr; 101(7):894-901. PubMed ID: 18241249
[TBL] [Abstract][Full Text] [Related]
26. Reversible kinetic analysis of Myc targets in vivo provides novel insights into Myc-mediated tumorigenesis.
Lawlor ER; Soucek L; Brown-Swigart L; Shchors K; Bialucha CU; Evan GI
Cancer Res; 2006 May; 66(9):4591-601. PubMed ID: 16651409
[TBL] [Abstract][Full Text] [Related]
27. [Inhibitory effect of the venom of spider Macrothele raveni on proliferation of human hepatocellular carcinoma cell line BEL-7402 and its mechanism].
Gao L; Feng W; Shan BE; Zhu BC
Ai Zheng; 2005 Jul; 24(7):812-6. PubMed ID: 16004806
[TBL] [Abstract][Full Text] [Related]
28. [Expressions of h-TERT, c-myc, PCNA and cell apoptosis in liver carcinogenesis].
Fu XM; Yang QX; Shao CK; Feng ZY
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):821-3. PubMed ID: 16793609
[TBL] [Abstract][Full Text] [Related]
29. Myc's other life: stem cells and beyond.
Laurenti E; Wilson A; Trumpp A
Curr Opin Cell Biol; 2009 Dec; 21(6):844-54. PubMed ID: 19836223
[TBL] [Abstract][Full Text] [Related]
30. RASSF1A expression inhibits the growth of hepatocellular carcinoma from Qidong County.
Xue WJ; Li C; Zhou XJ; Guan HG; Qin L; Li P; Wang ZW; Qian HX
J Gastroenterol Hepatol; 2008 Sep; 23(9):1448-58. PubMed ID: 17683489
[TBL] [Abstract][Full Text] [Related]
31. Molecular mechanisms of hepatocarcinogenesis in transgenic mouse models of liver cancer.
Calvisi DF; Thorgeirsson SS
Toxicol Pathol; 2005; 33(1):181-4. PubMed ID: 15805070
[TBL] [Abstract][Full Text] [Related]
32. Histologic characteristics and prognostic significance in small hepatocellular carcinoma with biliary differentiation: subdivision and comparison with ordinary hepatocellular carcinoma.
Aishima S; Nishihara Y; Kuroda Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
Am J Surg Pathol; 2007 May; 31(5):783-91. PubMed ID: 17460464
[TBL] [Abstract][Full Text] [Related]
33. Small-molecule c-Myc inhibitor, 10058-F4, inhibits proliferation, downregulates human telomerase reverse transcriptase and enhances chemosensitivity in human hepatocellular carcinoma cells.
Lin CP; Liu JD; Chow JM; Liu CR; Liu HE
Anticancer Drugs; 2007 Feb; 18(2):161-70. PubMed ID: 17159602
[TBL] [Abstract][Full Text] [Related]
34. Context-dependent hormone-refractory progression revealed through characterization of a novel murine prostate cancer cell line.
Watson PA; Ellwood-Yen K; King JC; Wongvipat J; Lebeau MM; Sawyers CL
Cancer Res; 2005 Dec; 65(24):11565-71. PubMed ID: 16357166
[TBL] [Abstract][Full Text] [Related]
35. RNAi-hTERT inhibition hepatocellular carcinoma cell proliferation via decreasing telomerase activity.
Zhang PH; Zou L; Tu ZG
J Surg Res; 2006 Mar; 131(1):143-9. PubMed ID: 16298398
[TBL] [Abstract][Full Text] [Related]
36. Identification of novel Myc target genes with a potential role in lymphomagenesis.
Marinkovic D; Marinkovic T; Kokai E; Barth T; Möller P; Wirth T
Nucleic Acids Res; 2004; 32(18):5368-78. PubMed ID: 15477387
[TBL] [Abstract][Full Text] [Related]
37. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
38. Antisense regulation of expression and transactivation functions of the tumorigenic HBx and c-myc genes.
Hung L; Kumar V
Biochem Biophys Res Commun; 2006 May; 344(1):293-9. PubMed ID: 16616001
[TBL] [Abstract][Full Text] [Related]
39. Distinct nuclear arrangement of active and inactive c-myc genes in control and differentiated colon carcinoma cells.
Harnicarová A; Kozubek S; Pacherník J; Krejci J; Bártová E
Exp Cell Res; 2006 Dec; 312(20):4019-35. PubMed ID: 17046748
[TBL] [Abstract][Full Text] [Related]
40. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
